Home > Insider Trading > Filing (0001573833-14-000001)

Filing Details

Accession Number:: 0001573833-14-000001
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-10-01 21:06:31
Reporting Period:: 2014-09-29

Filing Date:: 2014-10-01
Accepted Time:: 2014-10-01 21:06:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1267602	Alimera Sciences Inc	ALIM	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1573833	Patrick Lee	470 University Avenue Palo Alto CA 94301		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-09-29	240,662	$5.47	3,394,322	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-09-30	348,962	$5.42	3,045,360	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-09-30	4,100	$5.43	3,041,260	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-09-30	1,000	$5.50	3,040,260	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2014-10-01	26,467	$5.16	3,013,793	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Footnotes

Palo Alto Investors, LLC ("PAI LLC") is the General Partner of Micro Cap Partners, L.P. ("Micro Cap"), Palo Alto Healthcare Master Fund, L.P. ("Healthcare Master"), Palo Alto Healthcare Master Fund II, L.P. ("Healthcare Master II"), Palo Alto Healthcare Fund L.P. ("Healthcare LP"), Palo Alto Healthcare Fund II L.P. ("Healthcare II LP") and Palo Alto Micro Cap Liquidating Fund, L.P. ("Liquidating Fund").
Patrick Lee, M.D. is the co-managing member of PAI LLC.
Dr. Lee may be deemed to beneficially own the Common Stock, Series A Convertible Preferred Stock and Warrants owned directly by Micro Cap, Healthcare Master, Healthcare Master II and Liquidating Fund, and beneficially owned indirectly by Healthcare LP and Healthcare II LP. Dr Lee disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Reported holdings include the following held directly by Micro Cap, Healthcare Master, Healthcare Master II and Liquidating Fund: Micro Cap - 129,000 shares of Common Stock, 323,308 shares of Common Stock acquirable immediately upon conversion of 21,500 shares of Series A Convertible Preferred Stock, and and exercisable Warrant for 6,450 shares of Series A Convertible Preferred Stock, which could be immediately converted into 96,992 shares of Common Stock; [To be continued in Footnote (4)]
Healthcare Master -- 1,216,563 shares of Common Stock, 3,476,691 shares of Common Stock acquirable immediately upon conversion of 231,200 shares of the Series A Convertible Preferred Stock, and an exercisable Warrant for 69,360 shares of Series A Convertible Preferred Stock, which could be immediately converted into 1,043,007 shares of Common Stock; Healthcare Master II -- 1,668,230 shares of Common Stock, 5,222,556 shares of Common Stock acquirable immediately upon conversion of 347,300 shares of the Series A Convertible Preferred Stock, and an exercisable Warrant for 104,190 shares of Series A Convertible Preferred Stock, which could be immediately converted into 1,566,776 shares of Common Stock. [To be continued in Footnote (5)]
Healthcare LP owns 87.52% of the limited partnership interests in Healthcare Master. Healthcare II LP owns 72.80% of the limited partnership interests in Healthcare Master II.
The conversion price of Series A Convertible Preferred Stock into common stock is $2.66.
The amount or number of shares reported herein reflects the amount or number of shares of Series A Convertible Preferred Stock that may be acquired at an exercise price of $44 per share. Additionally, at the election of the holder, the Warrants provide for the option to purchase shares of Common Stock at an exercise price of $44 divided by the number of shares of Common Stock then issued or issuable upon conversion of one share of Series A Convertible Preferred Stock. [To be continued in Footnote (8)]
If the holder elects to exercise the Warrant to purchase Common Stock, it would be entitled to purchase up to the number of shares of Common Stock as would be issuable upon conversion of the shares of Series A Convertible Preferred Stock subject to the Warrant. Accordingly, whether the holder elects to exercise its option to purchase Series A Convertible Preferred Stock or Common Stock pursuant to the Warrant, neither the number of shares of Common Stock ultimately acquirable nor the percentage ownership in Alimera Sciences, Inc. would be impacted.
Series A Convertible Preferred Stock does not have an expiration date.
Warrant to purchase Series A Convertible Preferred Stock or Common Stock (right to buy) expires October, 2017.